Safety and efficacy of liraglutide in patients with obesity
A retrospective observational study across glycemic status groups
DOI:
https://doi.org/10.59736/IJP.23.03.965Keywords:
Glycemic Control, GLP-1 Receptor Agonist, Liraglutide, Obesity, Prediabetes, Type 2 Diabetes Mellitus, Weight LossAbstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as liraglutide, have demonstrated efficacy in weight reduction and glycemic control. However, comparative data across obese individuals with differing metabolic states non-diabetic (ND), prediabetic (pre-DM), and type 2 diabetes mellitus (T2DM) remain limited, particularly regarding hepatic, lipid, and safety outcomes. This study aimed at evaluating liraglutide’s efficacy in reducing body weight and improving metabolic parameters (HbA1c, lipid profile, liver enzymes) and its safety in obese individuals across these groups.
Methods: A prospective study was conducted on 120 obese patients receiving Liraglutide for six months (ND: n=7; pre-DM: n=16; T2DM: n=97). Baseline demographic, anthropometric, and biochemical parameters were recorded. Outcomes assessed at 3 and 6 months included weight, BMI, HbA1c, blood pressure, liver enzymes (ALT, AST), lipid profile, and adverse events. Between-group comparisons were performed using ANCOVA, adjusting for age, disease duration, and baseline metabolic variables.
Results: At baseline, patients with T2DM were older and had significantly higher HbA1c, ALT, total cholesterol (TC), and triglycerides (TG) compared with ND and pre-DM groups (p<0.05). Over six months, weight and BMI decreased significantly in all groups, with the greatest mean reduction observed in T2DM (–13.28 ± 8.22 kg), followed by pre-DM (–13.19 ± 9.34 kg), and ND (–6.43 ± 6.53 kg). Higher baseline HbA1c predicted greater weight loss in T2DM and pre-DM (p<0.001). Liraglutide was associated with reductions in ALT and AST across all groups, particularly in those with elevated baseline levels. Lipid improvements were most pronounced in T2DM, with significant reductions in LDL and TG.
Conclusion: Liraglutide therapy in obese patients led to significant weight loss and favorable effects on glycemic, hepatic, and lipid parameters across ND, pre-DM, and T2DM groups, supporting the broader role of Liraglutide in obesity and metabolic disease management.
References
Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Frontiers in endocrinology. 2023;14:1161521.
Ma C-X, Ma X-N, Guan C-H, Li Y-D, Mauricio D, Fu S-B. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovascular diabetology. 2022;21(1):74.
Abad-Jiménez Z, Vezza T. Obesity: A Global Health Challenge Demanding Urgent Action. Biomedicines. 2025;13(2):502.
Alfaris N, Alqahtani AM, Alamuddin N, Rigas G. Global Impact of Obesity. Gastroenterology clinics of North America. 2023;52(2):277-93.
Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217.
Sørensen TI, Martinez AR, Jørgensen TSH. Epidemiology of obesity. From obesity to diabetes: Springer; 2022. p. 3-27.
Murray CJ, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The lancet. 2020;396(10258):1223-49.
Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ global health. 2022;7(9):e009773.
Tilinca MC, Tiuca RA, Burlacu A, Varga A. A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review. Medicina. 2021;57(7):669.
Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. 2024;9(1):234.
Viljoen A, Bain SC. Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond. enm. 2023;38(1):25-33.
Qi QYD, Cox A, McNeil S, Sumithran P. Obesity medications: A narrative review of current and emerging agents. Osteoarthritis and Cartilage Open. 2024;6(2):100472.
Nikolic D, Patti AM, Giglio RV, Chianetta R, Castellino G, Magán-Fernández A, et al. Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study. Diabetes Therapy. 2022;13(3):453-64.
Seo Y-G. Side effects associated with liraglutide treatment for obesity as well as diabetes. Journal of Obesity & Metabolic Syndrome. 2020;30(1):12.
Zhang P, Liu Y, Ren Y, Bai J, Zhang G, Cui Y. The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis. African health sciences. 2019;19(3):2591-9.
Alsanea S, Alkofide H, Almadi B, Almohammed O, Alwhaibi A, Alrabiah Z, et al. Liraglutide's Effect on Weight Management in Subjects With Pre-diabetes: A Systematic Review & Meta-Analysis. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2024;30(8):737-45.
Committee ADAPP. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2023;47(Supplement_1):S20-S42.
Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, et al. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020;43(5):1085-93.
Bode BW. Design, findings and implications of the liraglutide Phase III clinical trial program. Clinical investigation. 2012;2:59-72.
Madsbad S. Liraglutide Effect and Action in Diabetes (LEAD™) trial. Expert Review of Endocrinology & Metabolism. 2009;4(2):119-29.
Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, et al. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation. 2018;138(25):2884-94.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):311-22
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ayesha Durrani, Nizamud Din Hazbullah, Arshad Hussain, Wardah Arshad, Bushra Haider, Aqsa Shuaib
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
